Outcome measure

Last updated March 07, 2022

An outcome measure, endpoint, effect measure or measure of effect is a measure within medical practice or research, (primarily clinical trials) which is used to assess the effect, both positive and negative, of an intervention or treatment.^[1]^[2] Measures can often be quantified using effect sizes.^[3] Outcomes measures can be patient-reported, or gathered through laboratory tests such as blood work, urine samples etc. or through medical examination.^[1] Outcomes measures should be relevant to the target of the intervention (be it a single person or a target population).^[2]

Depending on the design of a trial, outcome measures can be either primary outcomes, in which case the trial is designed around finding an adequate study size (through proper randomization and power calculation).^[1]Secondary or tertiary outcomes are outcome measures which are added after the design of the study is finalized, for example when data has already been collected. A study can have multiple primary outcome measures.^[1]

Outcome measures can be divided into clinical endpoints and surrogate endpoints where the former is directly related to what the goal of the intervention, and the latter are indirectly related.^[1]

Relevance

Outcome measures used in trials should consider relevance to the target of the study. In clinical trials such measures of direct importance for an individual may be survival, quality of life, morbidity, suffering, functional impairment or changes in symptoms.^[2]

Outcome measures can be divided into clinical endpoints which are directly relevant to the target and surrogate endpoints (also called "proxy measures"), which are indirectly related.^[1] Death from cardiovascular disease is an example of a clinical endpoint, whereas measurements of blood pressure, which is not normally associated with any symptoms, is a surrogate endpoint. Other examples of surrogate endpoints are blood lipoproteins and bone density.^[2]

Composite measures or combined measures are common in clinical research.^[1]^[2] The rationale is that combining different outcome measures gives greater statistical power. For example, the composite measure Killed or Seriously Injured" is often used in studies of road safety. While deaths are easier to count and are an outcome of undisputed importance, they are also much fewer than the number seriously injured; many of the "seriously injured" will not have experienced a major life event. However, composite measures should be used with care, particularly when surrogate endpoints are included.^[2] A statistically significant effect of a composite measure can often be explained solely by effects of a surrogate endpoint or a variable that is less relevant. It is also possible that composite measures may mask negative treatment effects of truly important outcomes, such as death or cardiovascular events.^[2]

Related Research Articles

Proof of concept (POC), also known as proof of principle, is a realization of a certain method or idea in order to demonstrate its feasibility, or a demonstration in principle with the aim of verifying that some concept or theory has practical potential. A proof of concept is usually small and may or may not be complete.

A cardiac stress test is a cardiological test that measures the heart's ability to respond to external stress in a controlled clinical environment. The stress response is induced by exercise or by intravenous pharmacological stimulation.

In clinical trials, a surrogate endpoint is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship. The National Institutes of Health (USA) defines surrogate endpoint as "a biomarker intended to substitute for a clinical endpoint".

The number needed to treat (NNT) is an epidemiological measure used in communicating the effectiveness of a health-care intervention, typically a treatment with medication. The NNT is the average number of patients who need to be treated to prevent one additional bad outcome. It is defined as the inverse of the absolute risk reduction, and computed as $, where is the incidence in the treated (exposed) group, and is the incidence in the control (unexposed) group. This calculation implicitly assumes monotonicity, that is, no individual can be harmed by treatment. The modern approach, based on counterfactual conditionals, relaxes this assumption and yields bounds on NNT.$

Clinical endpoints or clinical outcomes are outcome measures referring to occurrence of disease, symptom, sign or laboratory abnormality constituting a target outcome in clinical research trials. The term may also refer to any disease or sign that strongly motivates withdrawal of an individual or entity from the trial, then often termed a humane (clinical) endpoint.

In a clinical trial, the investigators must specify inclusion and exclusion criteria for participation in the study.

In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.

A patient-reported outcome (PRO) is a health outcome directly reported by the patient who experienced it. It stands in contrast to an outcome reported by someone else, such as a physician-reported outcome, a nurse-reported outcome, and so on. PRO methods, such as questionnaires, are used in clinical trials or other clinical settings, to help better understand a treatment's efficacy or effectiveness. The use of digitized PROs, or electronic patient-reported outcomes (ePROs), is on the rise in today's health research setting.

Intima–media thickness (IMT), also called intimal medial thickness, is a measurement of the thickness of tunica intima and tunica media, the innermost two layers of the wall of an artery. The measurement is usually made by external ultrasound and occasionally by internal, invasive ultrasound catheters. Measurements of the total wall thickness of blood vessels can also be done using other imaging modalities.

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with certain kinds of heart failure and chronic kidney disease.

The analysis of clinical trials involves many related topics including:

A glossary of terms used in clinical research.

The following outline is provided as an overview of and topical guide to clinical research:

Outcomes research is a branch of public health research, which studies the end results of the structure and processes of the health care system on the health and well-being of patients and populations. According to one medical outcomes and guidelines source book - 1996, Outcomes research includes health services research that focuses on identifying variations in medical procedures and associated health outcomes. Though listed as a synonym for the National Library of Medicine MeSH term "Outcome Assessment ", outcomes research may refer to both health services research and healthcare outcomes assessment, which aims at Health technology assessment, decision making, and policy analysis through systematic evaluation of quality of care, access, and effectiveness.

An imaging biomarker is a biologic feature, or biomarker detectable in an image. In medicine, an imaging biomarker is a feature of an image relevant to a patient's diagnosis. For example, a number of biomarkers are frequently used to determine risk of lung cancer. First, a simple lesion in the lung detected by X-ray, CT, or MRI can lead to the suspicion of a neoplasm. The lesion itself serves as a biomarker, but the minute details of the lesion serve as biomarkers as well, and can collectively be used to assess the risk of neoplasm. Some of the imaging biomarkers used in lung nodule assessment include size, spiculation, calcification, cavitation, location within the lung, rate of growth, and rate of metabolism. Each piece of information from the image represents a probability. Spiculation increases the probability of the lesion being cancer. A slow rate of growth indicates benignity. These variables can be added to the patient's history, physical exam, laboratory tests, and pathology to reach a proposed diagnosis. Imaging biomarkers can be measured using several techniques, such as CT, electroencephalography, magnetoencephalography, and MRI.

The instantaneous wave-free ratio is a diagnostic tool used to assess whether a stenosis is causing a limitation of blood flow in coronary arteries with subsequent ischemia. iFR is performed during cardiac catheterisation (angiography) using invasive coronary pressure wires which are placed in the coronary arteries that are to be assessed. Pressure wires are commonly used by interventional cardiologists to guide decisions to perform revascularization, either by stenting or bypass surgery.

Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).

The FACT-G is a patient-reported outcome measure used to assess health-related quality of life in patients undergoing cancer therapy. The FACT-G is the original questionnaire that led to the development of the larger Functional Assessment of Chronic Illness Therapy (FACIT) collection of quality of life instruments. The survey assesses the impacts of cancer therapy in four domains: physical, social/family, emotional, and functional. The FACT-G is also offered with additional questions measuring cancer-specific factors that may affect quality of life, leading to the creation of the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N), the Functional Assessment of Cancer Therapy - Lung (FACT-L), and 18 others.

Pediatric Early Warning Signs (PEWS) are clinical manifestations that indicate rapid deterioration in pediatric patients, infancy to adolescence. PEWS Score or PEWS System are objective assessment tools that incorporate the clinical manifestations that have the greatest impact on patient outcome.

References

1 2 3 4 5 6 7 Ross, David A.; Morrow, Richard H.; Smith, Peter G. (2015). Outcome measures and case definition. Oxford University Press. doi:10.1093/med/9780198732860.003.0012. ISBN 9780191797675.
1 2 3 4 5 6 7 Assessment of methods in health care - A handbook (PDF) (Preliminarily ed.). Swedish Agency for Health Technology Assessment and Assessment of Social Services. April 2018. pp. 18–19. Retrieved 2019-08-28.
↑ Tripepi, G.; Jager, K.J.; Dekker, F.W.; Wanner, C.; Zoccali, C. (October 2007). "Measures of effect: Relative risks, odds ratios, risk difference, and 'number needed to treat'". Kidney International. 72 (7): 789–791. doi: 10.1038/sj.ki.5002432 . PMID 17653136.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[:0-1] 1 2 3 4 5 6 7 Ross, David A.; Morrow, Richard H.; Smith, Peter G. (2015). Outcome measures and case definition. Oxford University Press. doi:10.1093/med/9780198732860.003.0012. ISBN 9780191797675.

[:1-2] 1 2 3 4 5 6 7 Assessment of methods in health care - A handbook (PDF) (Preliminarily ed.). Swedish Agency for Health Technology Assessment and Assessment of Social Services. April 2018. pp. 18–19. Retrieved 2019-08-28.

[3] Tripepi, G.; Jager, K.J.; Dekker, F.W.; Wanner, C.; Zoccali, C. (October 2007). "Measures of effect: Relative risks, odds ratios, risk difference, and 'number needed to treat'". Kidney International. 72 (7): 789–791. doi: 10.1038/sj.ki.5002432 . PMID 17653136.

[1]

[2]

[3]